GeminIQ Website Logo

Viewing ODTX free

Subscribe for full history, 90+ metrics, screener, watchlist...

Odyssey Therapeutics, Inc.

ODTX

Subscribe to unlock 17+ years of data

Financial Statements

Values in Millions ($)
2026-06-30
2026-03-31
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Financial statements beyond 3 years are for subscribers only.

Unlock 17+ years of income statements, balance sheets, and cash flow statements

Start 7-day free trial
Subscriber-only column
Series A Preferred Stock
-0
Series B Preferred Stock
-0
Series C Preferred Stock
-0
Series D Preferred Stock
-0
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value
8236
Marketable Securities Current
229140
Prepaid Expense And Other Assets Current
119
Assets Current
321185
Property Plant And Equipment Net
57
Operating Lease Right Of Use Asset
1718
Goodwill
1414
Finite Lived Intangible Assets Net
00
Marketable Securities Noncurrent
1220
Other Assets Noncurrent
45
Assets
484229
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current
88
Accrued Liabilities Current
159
Operating Lease Liability Current
55
Liabilities Current
2822
Operating Lease Liability Noncurrent
1921
Liabilities
6349
Redeemable Noncontrolling Interest Equity Preferre…
-704
Stockholders Equity
Common Stock Value
00
Additional Paid In Capital
1,08183
Retained Earnings Accumulated Deficit
-659-606
Accumulated Other Comprehensive Income Loss Net Of…
-1-0
Stockholders Equity
421-524
Liabilities And Stockholders Equity
484229
Common Stock Par Or Stated Value Per Share
00
Common Stock Shares Authorized
500365
Common Stock Shares Issued
483
Shares Outstanding
482

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Custom Table

0/5
Search a metric to start building a table

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Interactive Financial Visualizations

0/1
Search a metric to start building a visual

Subscribe to unlock 17+ years of data

Earnings Market Reaction

Fiscal Year
Q1 1 Month
Q1 2 Month
Q1 3 Month
Q2 1 Month
Q2 2 Month
Q2 3 Month
2026-9.69%-----

Earnings Market Reaction data beyond 3 years is for subscribers only.

Unlock the full earnings market reaction history

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics
2026-06-30
2026-03-31
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Metric history beyond 3 years is for subscribers only.

Unlock 17+ years of history across 90+ calculated metrics

Start 7-day free trial
Subscriber-only column
Liquidity Ratios
Current Ratio
11.36
8.33
Quick Ratio
10.98
7.91
Working Capital
293.17M
162.89M
Leverage & Debt
Debt to Equity
0.15
-0.09
Debt Ratio
0.13
0.21
Valuation Metrics
P/B TTM
1.34
-
Market Cap
566.48M
-
Enterprise Value
481.00M
-
Calculated Values
Net Debt
-85.48M
-39.17M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of data

Insider Transactions

2026-05-11Purchase
Owner: Coulter, James G, Winkelr…
Title: -
Shares: 1,388,889
Price/Share: $18.00
Value: $25,000,002.00
Shares Owned: 3,690,146
Relationship: Other
Ownership: Indirect
2026-05-11Purchase
Owner: Chu, Shelley
Title: -
Shares: 11,111
Price/Share: $18.00
Value: $199,998.00
Shares Owned: 11,111
Relationship: Director
Ownership: Direct
2026-05-11Purchase
Owner: Li, Nan (Ln)
Title: -
Shares: 1,111,111
Price/Share: $18.00
Value: $19,999,998.00
Shares Owned: 3,333,516
Relationship: Director
Ownership: Indirect
2026-05-11Purchase
Owner: George, Simeon, Sr One Ca…
Title: -
Shares: 555,555
Price/Share: $18.00
Value: $9,999,990.00
Shares Owned: 1,831,383
Relationship: TenPercentOwner
Ownership: Indirect
2026-05-11Sale
Owner: George, Simeon, Sr One Ca…
Title: -
Shares: 1,780
Price/Share: $18.00
Value: $32,040.00
Shares Owned: 440,981
Relationship: TenPercentOwner
Ownership: Indirect

Subscribe to unlock 17+ years of data

No institutional ownership data available.

Odyssey Therapeutics, Inc. (ODTX) — SEC Financial Statements & Analysis

Odyssey Therapeutics, Inc. (ODTX) is a biological products, (no diagnostic substances) company, incorporated in DE. Odyssey Therapeutics, Inc. trades on Nasdaq as: ODTX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Odyssey Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.15x, a Price-to-Book (P/B) ratio of 1.34x (TTM), at a market cap of $566.48M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity
0.15x
P/B TTM
1.34x
Market Cap
$566.48M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Odyssey Therapeutics, Inc. in?

Odyssey Therapeutics, Inc. (ODTX) operates in the Biological Products, (No Diagnostic Substances) industry.

What is ODTX's market cap?

Odyssey Therapeutics, Inc. (ODTX) has a market capitalization of $566.48M as of 2026-06-30.

What exchange does ODTX trade on?

Odyssey Therapeutics, Inc. (ODTX) trades on the Nasdaq.

Where is Odyssey Therapeutics, Inc. incorporated?

Odyssey Therapeutics, Inc. is incorporated in DE.

Wall Street's data.
Main Street's price.